Kennedy Capital Management LLC Buys 32,040 Shares of LeMaitre Vascular, Inc. $LMAT

Kennedy Capital Management LLC grew its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 247,907 shares of the medical instruments supplier’s stock after purchasing an additional 32,040 shares during the period. Kennedy Capital Management LLC’s holdings in LeMaitre Vascular were worth $20,105,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Barclays PLC boosted its holdings in shares of LeMaitre Vascular by 8.5% in the 4th quarter. Barclays PLC now owns 32,558 shares of the medical instruments supplier’s stock worth $2,640,000 after acquiring an additional 2,560 shares in the last quarter. Aptus Capital Advisors LLC boosted its holdings in shares of LeMaitre Vascular by 0.4% in the 4th quarter. Aptus Capital Advisors LLC now owns 67,783 shares of the medical instruments supplier’s stock worth $5,497,000 after acquiring an additional 291 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in shares of LeMaitre Vascular in the 4th quarter worth approximately $68,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of LeMaitre Vascular by 8.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 18,353 shares of the medical instruments supplier’s stock worth $1,486,000 after acquiring an additional 1,383 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after acquiring an additional 111,193 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently commented on LMAT shares. Roth Mkm reissued a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a report on Thursday, February 26th. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 20th. Finally, Barrington Research reissued an “outperform” rating and issued a $120.00 target price on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Price Performance

LMAT opened at $91.96 on Friday. The company has a quick ratio of 12.20, a current ratio of 14.32 and a debt-to-equity ratio of 0.42. LeMaitre Vascular, Inc. has a 12 month low of $79.00 and a 12 month high of $118.01. The company has a fifty day simple moving average of $104.09 and a 200 day simple moving average of $96.01. The stock has a market cap of $2.10 billion, a P/E ratio of 33.93, a P/E/G ratio of 2.55 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the prior year, the company earned $0.48 EPS. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, research analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Thursday, May 21st were given a $0.25 dividend. The ex-dividend date was Thursday, May 21st. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.1%. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, CEO George W. Lemaitre sold 27,881 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the completion of the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at approximately $155,428,765.11. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares of the company’s stock, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 54,453 shares of company stock worth $5,906,174 in the last quarter. Corporate insiders own 7.40% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.